Anti-smoking Vaccine in Second Phase
Nabi Biopharmaceuticals Announces Completion of NicVAX(TM) Phase II Clinical Trial Enrollment
21-Jul-2005 -
BRAY, Ireland. Nabi Biopharmaceuticals (Nasdaq: NABI) announced today that it has completed enrollment for its European-based NicVAX(TM) (Nicotine Conjugate Vaccine) Phase II dose-ranging study in smokers. NicVAX is a novel, innovative, and proprietary investigational vaccine being developed to ...
addiction
antibodies
carbon
+7